Minerva Neurosciences, Inc. (NERV) Stock Price & Analysis
Minerva Neurosciences, Inc. (NERV) fell 5.54% to USD 4.43 as of September 8, 2026 at 07:36 UTC, according to Nexqual real-time market data.
NERV last closed at USD 4.43; the session ranged USD 4.42–4.8 on volume of 78,437 shares. Market capitalization is —, with a 52-week range of USD 1.93–12.46 (NCM). Source: Nexqual, September 8, 2026 at 07:36 UTC.
Key Statistics (as of September 8, 2026 at 07:36 UTC)
| Price | USD 4.43 |
|---|---|
| Change | ▼ 5.54% (down) |
| Previous Close | USD 4.43 |
| Open | USD 4.43 |
| Day Range | USD 4.42 – 4.8 |
| 52-Week Range | USD 1.93 – 12.46 |
| Volume | 78,437 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (NERV)
Nexqual's technical model rates NERV "SELL" based on 2 bullish and 4 bearish signals across 128 daily candles, as of September 8, 2026 at 07:36 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 46.01 (neutral) |
| vs SMA50 | Below (USD 4.53) |
| MACD | 0.05 (positive) |
From Minerva Neurosciences, Inc.'s Latest SEC 10-K Filing (filed 2026-03-11)
Key Strengths & Strategy (as disclosed to the SEC)
- Moreover, the filing of an application for regulatory approval, including an NDA, or Biologics License Application ("BLA"), a Marketing Authorization Application ("MAA") in the EEA, or comparable foreign regulatory applications for approval, requires a payment of a significant user fee upon submission.
- Our product candidates and the activities associated with their development and commercialization in the United States, including, but not limited to, their advertising and promotion, will further be heavily scrutinized by the FDA, the United States Department of Justice, the United States Department of Health and Human Services' ("HHS's") Office of Inspector General, state attorneys general, 34 members of Congress and the public.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KALA | KALA BIO, Inc. | USD 0.51 | ▼ 3.06% |
| CTMX | CytomX Therapeutics, Inc. | USD 3.71 | ▼ 0.27% |
| CRVS | Corvus Pharmaceuticals, Inc. | USD 14.39 | ▲ 1.34% |
| ATXI | Avenue Therapeutics, Inc. | USD 0.54 | ▼ 4.56% |
| ALDX | Aldeyra Therapeutics, Inc. | USD 1.48 | ▼ 0.67% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 07:36 UTC. This page is informational and not investment advice.